We are pleased to announce a collaboration with Glantreo, a leader in advanced nano-featured materials, to integrate their functionalized SOLAD™ silica particles into our Atract™ T-cell activation kit.
The Atract™ kit is designed to activate and expand human T-cells using biocompatible composites with irreversibly bound CD3 and CD28 antibodies. This innovative approach mimics antigen-presenting cells while eliminating the need for magnetic particles, ensuring a cleaner, contamination-free cell output.
Glantreo, with nearly two decades of expertise in developing high-quality nano-featured materials, brings its deep technical knowledge and scalable manufacturing capabilities to this partnership. Their functionalized silica particles, widely used in applications such as chromatography, diagnostics, and drug delivery, are now expanding into the cell therapy space.
Dr. Luka Fajs, CEO of Bio-ReCell, commented:
"We view the relationship with Glantreo as a critical component in not only delivering our current Atract™ T-cell activation kit but also in assisting us develop and deliver our proprietary technology in T-Cell separation. This will allow us to continue to be dedicated in advancing cell therapy solutions. The Glantreo team’s deep technical skillset, backed up by strong production and quality systems and a positive can-do attitude make them an ideal partner and supplier for Bio-ReCell. This partnership is an important component of us being able to bring our current and future products to market."
John Hogan, Chief Commercial Officer of Glantreo, commented:
"Our collaboration with and supply of functionalised silica particles to Bio- ReCell is another example of Glantreo’s ability not only to rapidly develop materials that meet our customer’s technical requirements but also scale manufacturing, within a quality-driven environment, to meet commercial requirements. Furthermore, we are excited to be working with the Bio-ReCell team as part of their efforts to develop cutting-edge technologies for cell separation and activation."
This partnership highlights our dedication to providing next-generation tools for cell therapy manufacturing, ensuring efficiency, sterility, and reproducibility in T-cell processing.